Symbol | Exchange | Currency |
|---|
Investing.com – U.S. stocks were higher after the close on Friday, as gains in the Technology, Consumer Services and Industrials sectors led shares higher. At the close in NYSE,...
Investing.com – U.S. stocks were mixed after the close on Thursday, as gains in the Oil & Gas, Technology and Consumer Services sectors led shares higher while losses in the...
Investing.com – U.S. stocks were mixed after the close on Monday, as gains in the Consumer Goods, Utilities and Technology sectors led shares higher while losses in the Oil & Gas,...
GTx, Inc. (NASDAQ:GTXI) announced positive top-line data from a phase II study, evaluating lead pipeline candidate, enobosarm 3 mg (GTx-024), for treating postmenopausal women...
What a day for GTx, Inc. (NASDAQ:GTXI)! It had a fantastic run up on Monday, and is one of the better intraday charts I’ve seen in a while. It jumped 3.06, or 99%, to 6.15,...
GTx, Inc.’s (NASDAQ:GTXI) shares have climbed almost 99% after the company announced positive preliminary data from a phase II study, evaluating the lead pipeline candidate...
Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. Its product candidates include Zilovertamab, ONCT-808, ONCT-534 and ONCT-216. Zilovertamab is an investigational, humanized, monoclonal antibody designed to inhibit Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1), a growth factor receptor that is expressed on many tumors and that activates pathways to increased tumor proliferation, invasiveness and drug resistance, and bind to a specific functionally important epitope of ROR1. ONCT-808 is an autologous chimeric antigen receptor (CAR-T) therapy that targets ROR1 for the treatment of hematologic malignancies and solid tumors. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of advanced castration-resistant prostate cancer (CRPC) and other androgen receptor (AR) driven diseases.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Strong Buy | Buy | Sell |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Sell |
| Summary | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 0.1858 | 0.1914 | 0.183 | -0.0012 | -0.64% | 1.52M | NYSE | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 40.61 | 40.72 | 39.57 | +1.03 | +2.60% | 7.68M | NYSE | |||
| 1.99 | 2.02 | 1.97 | -0.010 | -0.50% | 179.85K | NASDAQ | |||
| 54.06 | 54.38 | 53.35 | +0.43 | +0.80% | 3.94M | NYSE | |||
| 8.39 | 8.56 | 8.30 | +0.08 | +0.96% | 4.49M | NYSE | |||
| 1.24 | 1.25 | 1.20 | +0.0500 | +4.20% | 5.25M | NYSE | |||
| 156.24 | 156.33 | 149.88 | +7.57 | +5.09% | 1.33M | NASDAQ | |||
| 119.48 | 119.70 | 116.40 | +4.41 | +3.83% | 8.49M | NASDAQ | |||
| 9.73 | 10.09 | 8.08 | +2.05 | +26.69% | 39.85M | NYSE | |||
| 9.26 | 9.29 | 8.84 | +0.380 | +4.28% | 383.87K | NASDAQ | |||
| 396.91 | 397.50 | 385.15 | +13.48 | +3.52% | 540.96K | NASDAQ | |||
| 56.44 | 56.52 | 53.27 | +2.68 | +4.99% | 3.84M | NYSE | |||
| 36.10 | 36.91 | 35.12 | +0.67 | +1.89% | 8.14K | NASDAQ | |||
| 115.99 | 116.01 | 114.01 | +3.05 | +2.70% | 5.03M | NYSE |